TJP Labs Completes Multi-Million Dollar Investment Round to Continue Global Expansion into Modern Oral Nicotine Manufacturing
August 31, 2021 11:24 ET
|
TJP Labs Inc.
PICKERING, Ontario, Aug. 31, 2021 (GLOBE NEWSWIRE) -- TJP Labs Inc. (“TJP Labs”), one of North America's leading full-service contract manufacturers of next-generation nicotine products, announced...
Recro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYS
August 17, 2021 07:00 ET
|
Recro Pharma, Inc.
Acquisition Expands Recro’s Global Customer Base and Service Offerings, Creates Bi-Coastal CDMO, Diversifies Pipeline and Revenue Sources, and Provides Additional Pathway for Continued Growth Webcast...
Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO
August 13, 2021 08:50 ET
|
Recro Pharma, Inc.
Combination of Synergistic Organizations Results in Broad CDMO Service with Capabilities Spanning from Pre-IND Development to Commercial Manufacturing and Packaging for Wide Range of Dosage Forms ...
Recro Announces Entry Into Letter of Intent for Acquisition of a Full Service CDMO
August 10, 2021 07:00 ET
|
Recro Pharma, Inc.
EXTON, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Reports Second Quarter 2021 Financial Results
August 09, 2021 16:05 ET
|
Recro Pharma, Inc.
Q2 2021 Highlighted by Revenues of $18.0 Million, an Increase of 16% Compared to Q2 2020 Revenue Multiple New Business Agreements Continue to Expand and Diversify Customer Base and Pipeline Company...
Recro To Report Financial Results for Second Quarter 2021 on August 9, 2021
August 02, 2021 16:05 ET
|
Recro Pharma, Inc.
EXTON, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Appoints Erica Raether as Vice President of People, Culture and ESG
July 20, 2021 07:00 ET
|
Recro Pharma, Inc.
EXTON, Pa., July 20, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Pharmaceutical Contract Manufacturing Industry M&A Implications and Outlook Report 2021: Objectives, M&A Activity 2018-2020, Target Characteristics, Acquirer Characteristics, Geography, Top Acquirers
July 16, 2021 07:48 ET
|
Research and Markets
Dublin, July 16, 2021 (GLOBE NEWSWIRE) -- The "Mergers and Acquisitions (M&A) in the Pharmaceutical Contract Manufacturing Industry - Implications and Outlook - 2021 Edition" report has been...
Global Pharmaceutical Contract Manufacturing Market Report 2021: Market to Reach $130.2 Billion by 2026 - API/Bulk Drugs Segments is Projected to Account for $81.5 Billion
July 15, 2021 07:23 ET
|
Research and Markets
Dublin, July 15, 2021 (GLOBE NEWSWIRE) -- The "Pharmaceutical Contract Manufacturing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global...
Recro Enters Development and Manufacturing Agreement With New Client
July 13, 2021 07:00 ET
|
Recro Pharma, Inc.
GAINESVILLE, Ga., July 13, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation...